By Fineline Cube 
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG: 0853), announced plans to acquire the remaining 49% stake in La Ronda (Shanghai Zuoxin Medical Technology Co., Ltd), a compatriot firm specializing in left atrial appendage device manufacturing. The transaction, valued at RMB 171 million (USD 24 million), will result in La Ronda becoming a wholly owned subsidiary of CardioFlow.
La Ronda’s Product Portfolio
Founded in 2019, La Ronda is a high-tech medical equipment company with a focus on developing and manufacturing left atrial appendage occluders. Its flagship products include the AnchorMan left atrial appendage occluder and the AnchorMan left atrial appendage guidance system. These devices have achieved remarkable commercial success, being applied in over 60 medical centers across 16 provinces and cities in China. The systems have demonstrated a 100% surgical success rate with no serious complications reported.
Strategic Growth and Market Expansion
The acquisition aligns with CardioFlow’s strategic goals to expand its presence in the cardiovascular medical device market. By fully integrating La Ronda, CardioFlow aims to leverage its innovative product portfolio and strengthen its position as a leading provider of left atrial appendage solutions.-Fineline Info & Tech